REGN

Regeneron Pharmaceuticals, Inc. NASDAQ

Healthcare ·Biotechnology ·US · regeneron.com

$709.21

Mkt Cap $73.1B

52w Low $476.49 67.5% of range 52w High $821.11

50d MA $755.59 200d MA $683.64

P/E (TTM) 16.3x

EV/EBITDA 13.8x

P/B 2.4x

Debt/Equity 0.1x

ROE 14.1%

P/FCF 19.8x

RSI (14) —

ATR (14) —

Beta 0.40

50d MA $755.59

200d MA $683.64

Avg Volume 688.9K

About

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including m…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 29, 2026	TNS	8.91	9.47	+6.3%	686.36	+1.0%	+3.0%	+2.2%	—	—	—	—	—
Jan 30, 2026	TNS	10.74	11.44	+6.5%	741.45	-1.2%	+1.8%	+2.4%	+4.5%	+3.4%	+5.9%	+6.7%	—
Oct 28, 2025	TNS	9.65	11.83	+22.6%	654.48	-0.6%	-0.2%	-0.1%	-0.4%	-1.9%	-4.0%	+19.2%	—
Aug 1, 2025	TNS	8.43	12.89	+52.9%	558.87	+1.5%	+2.3%	+2.0%	-0.7%	+0.2%	+0.7%	+3.4%	—
Apr 29, 2025	TNS	8.62	8.22	-4.6%	568.91	+1.8%	+5.2%	+3.7%	+6.5%	+6.1%	-1.8%	+6.4%	—
Feb 4, 2025	TNS	11.21	12.07	+7.7%	697.05	+1.7%	+2.8%	+3.6%	+1.9%	-1.0%	-4.5%	+0.2%	—
Oct 31, 2024	TNS	11.69	12.46	+6.6%	838.20	+0.8%	+0.6%	-1.1%	-1.0%	-2.6%	-1.6%	-9.1%	—
Aug 1, 2024	TNS	10.61	11.56	+9.0%	1093.14	+0.6%	-1.0%	-2.0%	-2.5%	-2.3%	+1.8%	+6.9%	—
May 2, 2024	TNS	10.17	9.55	-6.1%	937.61	-1.1%	+2.1%	+2.2%	+3.5%	+1.9%	+3.2%	+5.5%	—
Feb 2, 2024	TNS	10.73	11.86	+10.5%	945.18	-1.4%	-0.9%	-0.8%	-0.7%	+0.1%	+0.9%	+2.8%	—
Nov 2, 2023	TNS	10.72	11.59	+8.1%	818.79	+2.4%	-0.2%	+1.7%	+1.5%	+0.5%	-2.3%	+0.6%	—
Aug 3, 2023	TNS	9.84	10.24	+4.1%	771.45	+0.6%	-0.6%	+0.4%	+1.1%	+1.8%	+2.8%	+6.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 1	Guggenheim	Maintains	Buy → Buy	—	$707.06	$703.02	-0.6%	-0.8%	—	—	—	—
Apr 30	Barclays	Maintains	Overweight → Overweight	—	$686.36	$693.08	+1.0%	+3.0%	+2.2%	—	—	—
Apr 30	Truist	Maintains	Buy → Buy	—	$686.36	$693.08	+1.0%	+3.0%	+2.2%	—	—	—
Apr 30	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$686.36	$693.08	+1.0%	+3.0%	+2.2%	—	—	—
Apr 30	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$686.36	$693.08	+1.0%	+3.0%	+2.2%	—	—	—
Apr 23	TD Cowen	Maintains	Buy → Buy	—	$746.58	$750.99	+0.6%	+2.6%	+0.7%	-0.3%	-2.0%	-8.1%
Apr 23	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$746.58	$750.99	+0.6%	+2.6%	+0.7%	-0.3%	-2.0%	-8.1%
Apr 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$767.85	$771.48	+0.5%	-2.5%	-2.8%	-1.6%	-1.8%	-2.8%
Apr 8	Bernstein	Maintains	Outperform → Outperform	—	$760.27	$765.26	+0.7%	+2.0%	+1.0%	-1.5%	-1.8%	-0.6%
Mar 31	Truist	Maintains	Buy → Buy	—	$749.29	$757.47	+1.1%	+3.1%	+3.7%	+1.7%	+1.8%	+1.5%
Mar 2	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$781.67	$771.10	-1.4%	+1.2%	-1.9%	+0.7%	-2.1%	-2.8%
Feb 9	Guggenheim	Maintains	Buy → Buy	—	$785.51	$783.17	-0.3%	-0.7%	-3.9%	-0.8%	-0.2%	+2.2%
Feb 2	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$741.45	$732.92	-1.2%	+1.8%	+2.4%	+4.5%	+3.4%	+5.9%
Feb 2	JP Morgan	Maintains	Overweight → Overweight	—	$741.45	$732.92	-1.2%	+1.8%	+2.4%	+4.5%	+3.4%	+5.9%
Feb 2	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$741.45	$732.92	-1.2%	+1.8%	+2.4%	+4.5%	+3.4%	+5.9%
Feb 2	Truist	Maintains	Buy → Buy	—	$741.45	$732.92	-1.2%	+1.8%	+2.4%	+4.5%	+3.4%	+5.9%
Feb 2	Oppenheimer	Maintains	Outperform → Outperform	—	$741.45	$732.92	-1.2%	+1.8%	+2.4%	+4.5%	+3.4%	+5.9%
Feb 2	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$741.45	$732.92	-1.2%	+1.8%	+2.4%	+4.5%	+3.4%	+5.9%
Jan 22	Evercore ISI	Maintains	Outperform → Outperform	—	$749.33	$750.34	+0.1%	+0.8%	+0.6%	+1.8%	+2.9%	+0.2%
Jan 8	Truist	Maintains	Buy → Buy	—	$812.27	$805.81	-0.8%	-1.4%	-1.9%	-5.5%	-6.6%	-7.2%
Jan 7	BofA Securities	Upgrade	Underperform → Buy	—	$776.54	$786.18	+1.2%	+4.6%	+3.2%	+2.6%	-1.1%	-2.3%
Dec 12	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$746.80	$741.59	-0.7%	-0.7%	+0.8%	-0.1%	+0.4%	+0.3%
Dec 10	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$692.58	$695.06	+0.4%	+4.9%	+7.8%	+7.0%	+8.7%	+7.8%
Dec 4	Canaccord Genuity	Maintains	Buy → Buy	—	$723.67	$732.45	+1.2%	-0.1%	-0.7%	-2.8%	-4.3%	+0.4%
Dec 4	BMO Capital	Maintains	Outperform → Outperform	—	$723.67	$732.45	+1.2%	-0.1%	-0.7%	-2.8%	-4.3%	+0.4%
Dec 3	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$742.00	$730.36	-1.6%	-2.5%	-2.6%	-3.2%	-5.2%	-6.7%
Nov 24	Scotiabank	Maintains	Sector Perform → Sector Perform	—	$755.90	$759.05	+0.4%	+0.7%	+4.2%	+3.8%	+3.2%	-0.8%
Nov 20	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$702.75	$725.00	+3.2%	+4.9%	+7.6%	+8.4%	+12.0%	+11.6%
Nov 7	UBS	Maintains	Neutral → Neutral	—	$646.87	$650.35	+0.5%	+1.6%	+1.2%	+4.3%	+5.4%	+7.4%
Oct 29	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$654.48	$650.41	-0.6%	-0.2%	-0.1%	-0.4%	-1.9%	-4.0%
Oct 29	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$654.48	$650.41	-0.6%	-0.2%	-0.1%	-0.4%	-1.9%	-4.0%
Oct 29	BofA Securities	Maintains	Underperform → Underperform	—	$654.48	$650.41	-0.6%	-0.2%	-0.1%	-0.4%	-1.9%	-4.0%
Oct 29	Citigroup	Maintains	Buy → Buy	—	$654.48	$650.41	-0.6%	-0.2%	-0.1%	-0.4%	-1.9%	-4.0%
Oct 29	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$654.48	$650.41	-0.6%	-0.2%	-0.1%	-0.4%	-1.9%	-4.0%
Oct 29	Guggenheim	Maintains	Buy → Buy	—	$654.48	$650.41	-0.6%	-0.2%	-0.1%	-0.4%	-1.9%	-4.0%
Oct 23	Canaccord Genuity	Maintains	Buy → Buy	—	$584.74	$579.68	-0.9%	-1.5%	-1.2%	+0.1%	+11.9%	+11.7%
Oct 14	Canaccord Genuity	Maintains	Buy → Buy	—	$557.73	$556.92	-0.1%	+2.7%	+3.4%	+2.1%	+3.6%	+3.4%
Oct 13	Citigroup	Maintains	Buy → Buy	—	$564.63	$551.50	-2.3%	-1.2%	+1.4%	+2.1%	+0.8%	+2.4%
Oct 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$569.90	$569.29	-0.1%	-0.9%	-2.1%	+0.5%	+1.1%	-0.1%
Oct 8	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$583.24	$584.01	+0.1%	-3.3%	-2.3%	-3.2%	-4.4%	-1.8%
Aug 27	Bernstein	Maintains	Outperform → Outperform	—	$587.65	$591.87	+0.7%	-0.1%	-1.4%	-1.2%	-1.7%	-4.1%
Aug 27	Jefferies	Maintains	Buy → Buy	—	$587.65	$591.87	+0.7%	-0.1%	-1.4%	-1.2%	-1.7%	-4.1%
Aug 11	Truist	Maintains	Buy → Buy	—	$563.00	$561.52	-0.3%	-3.0%	-1.1%	-0.3%	+0.5%	+3.1%
Aug 4	Morgan Stanley	Maintains	Overweight → Overweight	—	$558.87	$566.98	+1.5%	+2.3%	+2.0%	-0.7%	+0.2%	+0.7%
Aug 4	BMO Capital	Maintains	Outperform → Outperform	—	$558.87	$566.98	+1.5%	+2.3%	+2.0%	-0.7%	+0.2%	+0.7%
Aug 4	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$558.87	$566.98	+1.5%	+2.3%	+2.0%	-0.7%	+0.2%	+0.7%
Aug 4	Guggenheim	Maintains	Buy → Buy	—	$558.87	$566.98	+1.5%	+2.3%	+2.0%	-0.7%	+0.2%	+0.7%
Jul 23	Canaccord Genuity	Maintains	Buy → Buy	—	$560.93	$568.12	+1.3%	+2.0%	+0.7%	+0.4%	-0.4%	-0.5%
Jul 11	UBS	Maintains	Neutral → Neutral	—	$559.76	$558.39	-0.2%	+1.4%	+1.9%	-2.1%	-2.1%	-1.7%
Jul 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$552.58	$554.38	+0.3%	+1.3%	+2.7%	+3.3%	-0.8%	-0.8%

Recent Filings

8-K

Unknown — 8-K Filing

This boilerplate 8-K filing contains only standard legal disclaimers and forward-looking statement warnings, providing no material information about Regeneron's business operations or financial performance that would impact stock valuation.

Apr 8

8-K

Opko Health Inc. -- 8-K Filing

OPKO Health reported fourth-quarter 2025 results and is hosting a conference call to discuss financial performance and business developments with investors.

Feb 26

8-K · 5.02 !!! Very High

AtaiBeckley Inc. -- 8-K 5.02: Executive Change

AtaiBiomedicines appointed Michael Faerm as CFO and principal accounting officer, strengthening financial leadership amid the company's clinical development programs.

Feb 19

Data updated apr 26, 2026 10:23pm · Source: massive.com